To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma
Status:
Unknown status
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to analyze factors affecting Hepatitis B Virus (HBV)
reactivation in anti-HBc positive patients with Non-Hodgkin's lymphoma treated with rituximab
and compare HBV reactivation rates by duration of prophylactic treatment with tenofovir to
contribute to the establishment of an effective prevention strategy.